Pfizer Inc. (PFE) — closed signal from September 6, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 5, 2025.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published September 6, 2025
Pfizer's shares have dropped a lot and may be ready for a short-term bounce. Trading has been heavier than normal, which often means many sellers are finished, letting prices recover. The company also participates in growing areas like freeze-dried injectable medicines, which helps set a base. With overall mood calm, we look for a slow climb over the next 3 months while keeping risk tight.
Primary drivers
- Price fell sharply and looks due to rebound, based on recent trading behavior
- Much heavier trading than usual suggests many sellers may be done
- Growth in freeze-dried injectable medicines can support future sales
- Large, steady drug maker that can hold up better in shaky markets
How it played out
PFE: thesis partly played out inside the window
Lyra published PFE at 24.45 on 2025-09-06 with a short-term 12% expected move. The thesis looked for a slow climb over the next 3 months. It pointed to a sharp prior drop, heavier trading than usual, possible support from freeze-dried injectable medicines, and Pfizer's scale as a steadier drug maker.
Inside the window, PFE peaked at 27.21 on 2025-10-03. That was an 11.3% gain, below the expected 12% move, though the peak price was above the 26.91 target. It ended at 26.03 on 2025-12-05. The thesis partly played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.